



















Achievement of Secondary Prevention Goals 6 to 9 months after Acute 





Student Number: GRFBRA002 
 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
In partial fulfilment of the requirements for the degree 
 
MASTER OF MEDICINE (MMed) 
 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
 
 
Date of Submission: 16/05/2014 
Supervisor: Professor Mpiko Ntsekhe 
 
Department of Medicine 
H46 Old Main Building, Groote Schuur Hospital 











The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 











	   	  
DECLARATION 
 
I, Bradley Paul Griffiths, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where 
acknowledgements indicate otherwise) and that neither the whole work nor 
any part of it has been, is being, or is to be submitted for another degree in 
this or any other university. 
I empower the university to reproduce for the purpose of research either the 











Good evidence exists to support the use of secondary prevention medications 
(aspirin, HMG-CoA reductase inhibitors [statins], beta-blockers and angiotensin-
converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs]) 
and smoking cessation in patients after acute coronary syndromes. At present, 
little is known about adherence to medication and smoking behaviour after 
discharge in South Africa. This information is essential to optimising both in-
patient care and post-discharge planning of these patients. 
 
Methods 
We conducted a cross sectional analysis of all patients discharged from the 
Groote Schuur Hospital Coronary Care Unit with a diagnosis of acute coronary 
syndrome between 15 November 2011 and 15 April 2012. A follow up 
telephone call was performed 6 to 9 months after discharge, and a standardized 
questionnaire completed detailing current medication use, reasons for non-
adherence, and smoking status at time of the interview. 
 
Results 
Prescribing of secondary prevention medications at discharge was found to be 
high (aspirin 94.5%, statins 95.7%, beta blockers 85.4%, ACEIs/ARBs 85.9%), 
and 70.7% of patients were discharged on a combination of all 4 drugs. At 6 to 
9 month follow-up, the proportion of patients using these medications had 
reduced by 8.9% for aspirin, 10.1% for statins, 6.2% for beta-blockers and 
17.9% for ACEIs/ARBs. Only 47.2% remained on all 4 drugs, a reduction of 
23.5%. Of the 56% of patients who were smokers on admission to hospital, 
31% had stopped smoking at the time of interview.  
 
Conclusions 
Despite high rates of pre-discharge prescription of recommended therapy 
following admissions for acute coronary syndromes, we observed a significant 
decline in adherence rates 6 to 9 months post discharge and a poor rate of 
	   	  
smoking cessation. An exploration of possible reasons for these findings 
suggests that efforts to educate patients about the importance of long-term 
adherence need to be improved. Furthermore, more effective interventions are 
needed to improve smoking cessation than in-hospital reminders about the 
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PART A: PROTOCOL 
 
Title: Achievement of secondary prevention goals 6 to 9 months after acute 
coronary syndrome – a retrospective, cross-sectional analysis 
 
Principal Investigator: Dr Bradley Griffiths, Registrar, Department of Internal 
Medicine, Groote Schuur Hospital 
Supervisor: Dr Mpiko Ntsekhe, Consultant Cardiologist and Head of Cardiac 
Cath Lab, Groote Schuur Hospital 
 
Problem 
The use of evidence-based medicines (aspirin, statin, ACE-inhibitor, beta-
blocker), and cessation of smoking after acute coronary syndrome (ACS) is 
known to reduce adverse outcomes[1-5], yet attainment of these goals in patients 
after discharge is often disappointing[6-9].  The reasons for this are complex and 
vary according to the population studied[10-11]. 
 
Justification 
Preventable adverse outcomes after ACS, particularly repeat admissions to 
hospital and reduction in functional capacity, lead to increased strain on already 
overburdened healthcare and social welfare systems. The simple interventions 




To assess the self-reported adherence of patients discharged from the Groote 
Schuur Hospital Coronary Care Unit (GSH CCU) with a diagnosis of ACS to 
prescribed discharge medication, as well as self-reported smoking status, at 6 
to 9 months post-discharge. 
 
Secondary objectives 
To identify factors that may be responsible for poor attainment of these goals. 
 




Study design: Cross-sectional, analytical study, with retrospective subject 
identification. 
Subject selection: Medical record analysis to include all patients discharged 
alive from the GSH CCU 6 to 9 months previously with a diagnosis of ACS. This 
time frame may need to be extended to enroll more patients if numbers are 
insufficient for statistical significance.  
Measurement: Data collection will take place in the form of a standardized 
questionnaire populated by retrospective data collected from the medical record, 
specifically: 
• Demographics 
• ACS diagnosis (UA/NSTEMI/STEMI) and in-hospital management 
• Comorbidities 
• Factors which will be compared in telephonic interview pertaining to 
secondary prevention goals: 
o Admission medication 
o Admission smoking status 
Further data collection in the form of a telephonic interview will then be 
performed to ascertain achievement of secondary prevention goals, specifically: 
• Medication use 
• Reason(s) for non-compliance (if relevant) 
• Smoking status 
The specific wording of the questions is attached (Appendix 1). These will be 
piloted on similar subjects who fall outside the research time frame, and minor 
changes may be made prior to formal data collection. A sample data capture 
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Ethics 
A full explanation of the nature of the study will be given to the subject at the 
beginning of the telephonic interview. This will leave no confusion as to the role 
of the interviewer as data-capturer rather than health service provider. Each 
subject will then be given the opportunity to give verbal informed consent, or 
withdraw from the interview if they so wish.  
If behavior hazardous to health is picked up in the interview (ongoing smoking, 
medication non-adherence), the subject will be encouraged to alter this 
behavior at the end of the interview. 
Anonymity will be maintained by writing the name of the subject only on the 
hand written data capture sheet. Subject identification in electronic capture will 
be by way of a coding system. Hand written data capture sheets will be 
accessible only to the Principal Investigator. 
 
Analysis 
Data analysis will be performed in conjunction with Dr Maia Lesosky from the 
Department of Internal Medicine, looking specifically at medication adherence 
and smoking. 
 
Reporting and Implementation 
The results of the study will be presented to the Department of Cardiology in the 
appropriate forum. Publication will be attempted in a reputable journal. 
 
Funding 
Costs directly related to the study, such as telephone calls, will be covered by a 
R5000 grant from the Department of Internal Medicine. Spending will be 
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PART B: STRUCTURED LITERATURE REVIEW 
 
Objectives  
The objectives of this literature review are: 
• To provide an overview of the burden of ischemic heart disease (IHD) in 
South Africa (SA) and its contribution to morbidity and mortality 
• To provide an overview of the importance of secondary prevention 
medication after recent acute coronary syndrome (ACS)  
• To provide an overview of the importance of smoking cessation in 
patients with a recent ACS 
• To provide an overview of what is known about patient and non-patient 
factors that influence adherence to medication 
• To identify the different methods available to measure medication 
adherence rates and how best to use them in a research setting 
• To identify the different methods available to measure smoking cessation 
rates and how best to use them in a research setting  
• To explore what is known about medication adherence in patients after 
ACS in SA  
• To explore what is known about smoking cessation rates in patients after 
ACS in SA 
 
Literature Search Strategy 
PubMed and Google Scholar were searched using a combination of the 
following terms: ‘acute coronary syndrome’, ‘ischaemic heart disease’, ‘coronary 
artery disease’, ‘burden of disease’, ‘South Africa’, ‘Sub-Saharan Africa’, 
‘secondary prevention’, ‘medication’, ‘adherence’, ‘smoking’ and ‘cessation’. 
Studies referenced from the articles found in the initial search were also 
reviewed for relevance and inclusion in the literature review. Articles were 
accessed through the UCT Medical Library ezproxy service.  
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Inclusion and Exclusion Criteria 
Preference was given to English articles published in peer-reviewed journals 
providing the most recent, comprehensive, and up to date data on the listed 
objectives. Specific emphasis was placed on data from South Africa, or 
countries with similar income profiles where data from South Africa was not 
available. Where available, meta-analyses combining the largest evidence base 
were used. 
Studies not in English and not published in peer-reviewed journals were not 
considered for inclusion in this literature review.  
 
Summary of the Literature 
Burden of Disease 
In the first national burden of disease study in 2000, IHD was found to be the 
single leading cause of death in the Western Cape (12%), followed by stroke 
(8.8%) and HIV/AIDS (8.4%), and deaths from non-communicable diseases 
(NCDs) accounted for a larger proportion of deaths in the Western Cape (58%) 
when compared to the rest of South Africa (38%)[1].  In a subsequent study, 
mortality from IHD in Cape Town was found to be very similar to HIV/AIDS (76 
vs. 83 deaths per 100 000 population, respectively), and IHD featured as the 
leading cause of death from NCDs[2]. We are awaiting the full data from the 
second national burden of disease study, but initial estimates show a downward 
trend in mortality from HIV/AIDS due to the extensive antiretroviral (ARV) 
rollout[3]. With this in mind we can expect an even higher contribution of non-
communicable diseases to overall mortality.  
Two studies looking at the prevalence of IHD in Sub-Saharan Africa both came 
to the conclusion that good epidemiological evidence is lacking, and current 
evidence suggests the prevalence of IHD to be low compared to 
cerebrovascular disease and other causes of heart disease[4,5]. Despite this, it is 
accepted that with the epidemiologic transition from developing to developed 
countries we can expect a higher incidence of NCDs, particularly IHD and 
cerebrovascular disease, in future. This is mainly attributed to high-fat diet, 
tobacco smoking and sedentary lifestyles[6]. It is predicted that NCD’s will 
become the leading cause of death in Africa by 2030[7], and this view is 
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supported by World Health Organisation (WHO) predictions that the highest rate 
of increase of NCDs in the next decade will be in Africa[8]. 
It is thus evident from the literature that IHD is a considerable health burden in 
the Western Cape Province of South Africa, and we can expect the burden of 
disease in other provinces of South Africa and other African countries to 
increase as these areas become more developed and mortality from HIV 
infection is reduced.  
 
Importance of Secondary Prevention Medication after Acute Coronary 
Syndrome: 
Acetylsalicylic acid (aspirin) as antiplatelet therapy is proven to confer a survival 
benefit in patients with ACS[9]. Treatment with 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (statins) not only lowers lipid 
levels, but also has beneficial effects on platelet adhesion, thrombosis, 
endothelial function, inflammation, and plaque stability, providing mortality and 
morbidity reduction after ACS beyond what is expected for the degree of lipid 
reduction alone[10]. Beta-blockers (BB) act by competitively blocking the effects 
of catecholamines on cell membrane beta-receptors, and have been proven to 
reduce mortality in patients with ACS with compensated heart failure and left 
ventricular dysfunction[11], and those undergoing percutaneous coronary 
intervention (PCI)[12]. Angiotensin converting enzyme inhibitors (ACEIs) have 
been shown to reduce 30-day mortality after ACS[13] and confer long-term 
reduction in vascular events in patients with atherosclerosis[14]. 
In a trial of 1358 patients with acute coronary syndromes discharged 
consecutively from a single institution, the use of combination therapy with 
aspirin, statins, BBs and ACEIs or angiotensin receptor blockers (ARBs) was 
independently and strongly associated with a 72% to 87% reduction in 6-month 
mortality[15]. Another trial of 1521 patients discharged after ACS on aspirin, 
beta-blockers and statins showed a reduction in 1-year survival from 97.7% to 
88.5% in those discontinuing all medication after 1 month[16]. Three other trials 
have also demonstrated a relationship between discontinuation of evidence 
based combination therapy after ACS and increased mortality[17-19]. 
This and other evidence has led the European Society of Cardiology (ESC) and 
American College of Cardiology (ACC)/American Heart Association (AHA) 
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guidelines to recommend that aspirin, statin and BB therapy should be initiated 
and continued indefinitely after acute coronary syndrome, and ACEI or ARB 
therapy should be considered in all patients unless contraindicated[20-22]. 
Thienopyridine therapy for 12 months is also recommended in these guidelines 
but was not yet available for all patients at our institution at the time of the study.  
 
Importance of Smoking Cessation after Acute Coronary Syndrome: 
Cigarette smoking is a well-established risk factor for the development of 
cardiovascular disease[23]. Smoking cessation in patients with established 
coronary artery disease has been studied to determine if this is of benefit in the 
secondary prevention of ischaemic coronary events and death.  
Two studies from Israel looked at the effect of smoking cessation and long-term 
mortality in patients with IHD. The first looked at 3122 patients with established 
coronary artery disease and found a significant increase in sudden cardiac 
death (8.1% vs. 4.6%) and all cause mortality (24.9% vs. 14.9%) in ongoing 
smokers when compared to non-smokers. Quitting smoking reduced this risk to 
that comparable with non-smokers over an 8-year period[24]. The second, a 
population-based cohort study, followed 1521 patients after first MI and found 
that smoking cessation after the acute event led to a significant mortality 
reduction over a 13 year period compared to ongoing smoking (HR 0.63; 95% 
CI 0.48 – 0.82). On multivariable adjustment they also found the intensity of 
smoking to be directly linked to mortality, with a reduction of 5 cigarettes per 
day in those who continued to smoke leading to an 18% (95% CI 9% to 25%) 
decline in mortality risk over the same period[25].  
Two studies have looked at the short- to medium-term effect of smoking 
cessation after ACS. A study of 18 809 patients from 41 countries enrolled in 
the Organization to Assess Strategies in Acute Ischaemic Syndromes (OASIS) 
5 trial found that quitting smoking after an episode of unstable angina or non-ST 
elevation myocardial infarction (NSTEMI) resulted in a significantly reduced risk 
of subsequent myocardial infarction within 6 months compared to ongoing 
smokers (OR 0.57; 95% CI 0.36 – 0.89)[26]. Another study of 1206 patients 
enrolled in in-patient cardiac rehabilitation programs after ACS at 2 sites in 
Germany found a dose-response relationship between smoking after ACS and 
occurrence of secondary cardiovascular event (death due to cardiovascular 
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disease, non-fatal MI, ischaemic cerebrovascular event or coronary 
revascularization procedure) within 1 year[27]. 
A systematic review looking specifically at the mortality risk reduction 
associated with smoking cessation in patients with coronary artery disease 
(unstable angina [UA], previous MI or chronic stable angina) found an overall 
risk reduction of 36% when compared to ongoing smoking in the 20 studies 
assessed. This appeared relatively consistent between the studies, regardless 
of the type of index cardiac event or years in which the study was conducted[28].   
It is thus clear from current evidence that smoking cessation after ACS confers 
a significant survival benefit and reduces the incidence of repeat coronary 
events.  
 
Factors that Influence Adherence to Medication: 
The reasons for poor medication adherence are often multifactorial. The World 
Health Organization (WHO) has categorized potential reasons for medication 
non-adherence into 5 broad groups, including patient, condition, therapy, 
socioeconomic and health system-related factors[29]. 
Patient factors include younger age, nonwhite race, and depression. Conditions 
that are asymptomatic or chronic in nature that require long-term therapy, and 
therapy-related factors including regimen complexity and medication side 
effects, are shown to have a higher rate of non-adherence. Lower education 
level and low health literacy are socioeconomic factors that also correlate with 
poor adherence[30]. 
Healthcare system factors also have a significant role to play in medication 
adherence in chronic illness. Problems identified include patients not being able 
to list their medication at hospital discharge[31], discrepancies between pre-
hospital, discharge, and post-hospital medication regimens[32], and care 
providers not asking directly about medication taking at scheduled visits[33]. 
The vast majority of publications in South Africa looking at adherence to 
medication is in the setting of tuberculosis and antiretroviral medication for HIV 
infection. A study looking at general medication adherence in the context of the 
South African primary health care system found that socioeconomic factors, 
specifically low income and competing demands for time, and psychological 
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factors, such as social support and health literacy, are important factors that 
play significant roles in adherence to medication in our setting[34]. 
 
Measuring Medication Adherence: 
Adherence to a medication regimen is generally defined as the extent to which 
patients take medications as prescribed by their health care providers. The 
methods available for measuring adherence can be broken down into direct and 
indirect[35]. Examples of direct measurements are directly observed therapy, 
measurement of a drug or its metabolite in body fluid, or measurement of a 
biological marker added to the drug formulation. Although more robust than 
indirect methods, these direct methods are expensive, time-consuming and still 
susceptible to distortion by the patient, for example by hiding pills in the mouth 
and discarding later. Indirect methods of measurement of adherence include 
self-report (interview, questionnaire or medication diary), assessment of clinical 
response, pill counts, ascertaining pharmacy refill rates and electronic 
medication monitors. Each method has advantages and disadvantages (Table 
1), and no method is considered the gold standard[36]. 
A systematic review of the literature looking at the suitability of measures of 
self-reported medication adherence found 58 different self-reported measures 
of adherence and concluded that there is a need for a single measure in the 
routine continual monitoring of adherence[37]. Self-reported questionnaires 
(SRQs) were found to have moderate to high concordance with electronic 
measures in 12 of 16 comparisons (75%) in one review, and this was found to 
be superior to interview-based self-reports[38]. A recent meta-analysis found 
moderate correlation between SRQs and electronic medication event 
monitoring systems (MEMS)[39]. The United Kingdom National Institute for 
Health and Clinical Excellence (NICE) guidelines have identified that while other 
measures of adherence are appropriate for clinical trials of new drugs, self-
report is an appropriate tool for clinical practice[40].  
 
Measuring Smoking Cessation Rates: 
Cotinine is the major metabolite of nicotine and can be measured in various 
biological specimens including plasma, saliva and urine. As a biomarker it is 
highly sensitive and specific for tobacco use in the absence of nicotine 
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replacement therapy, and is recommended as the best biomarker to confirm 
reported smoking cessation[41]. A systematic review of 67 studies looking at the 
relationship between self-reported smoking and cotinine-assessed smoking 
status found that self-report tended to underestimate smoking rates, and this 
was probably due to social desirability bias. However there was considerable 
variability between the population group studied and the medium in which the 
biological sample was measured[42].  
We could find two studies looking specifically at the accuracy of self-reported 
smoking status in patients with coronary artery disease. A study from Scotland 
compared the validity of self-reported smoking status in 665 patients with ACS 
at the time of admission with members of the general public. On univariate 
analysis, the percentage of “smoking deceivers” (self-reported non-smokers but 
serum cotinine levels more than 12ng/ml) in the ACS and general public group 
were similar (11% vs. 12%), but following adjustment for age, sex and exposure 
to environmental tobacco smoke, ACS patients were more likely to misclassify 
themselves (OR 14.06, 95% CI 2.12-93.01, p=0.006). The probability of 
misclassification was found to fall significantly with increasing age in the ACS 
group[43]. A study from a single tertiary centre in Sweden assessed smoking 
biomarkers in 260 self-reported previous smokers who had previously been 
admitted with an ischaemic event and were following up at a routine nurse-run 
secondary prevention clinic. They found a good correlation between self-
reported smoking status and biochemical validation, with only 17 patients 
(6.5%) testing positive for exhaled carbon monoxide or serum cotinine when 
claiming to be non-smokers[44]. 
It is thus evident from the literature that the ideal method of assessing smoking 
status in medical research is with biochemical validation with cotinine 
measurement. However, this method comes with a time and cost burden that 
makes it difficult to use in large population-based studies, or studies with limited 
funding. Self-report generally underestimates smoking rates, however in 
patients with coronary artery disease at least one study suggests that this 
under-reporting may be reasonably low.  
Adherence to Secondary Prevention Medication after Acute Coronary 
Syndrome in South Africa: 
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There were no published studies looking specifically at the adherence to 
secondary prevention medication after ACS in South Africa. The best data 
available to us comes from the Prospective Rural Epidemiological (PURE) study, 
where use of secondary prevention medication in patients with any given history 
of coronary artery disease (myocardial infarction [MI], coronary artery bypass 
grafting or PCI) was assessed in countries grouped according to stage of 
economic development. South Africa was grouped with 6 other upper middle-
income countries as per the World Bank Country Classifications[45]. In this group, 
usage of secondary prevention medications in patients with coronary artery 
disease was low: 27.1% for antiplatelet agents, 31% for BB, 30.9% for 
ACEI/ARB and 21.1% for statins. These figures were even lower when Africa as 
a whole was compared to other countries (antiplatelet agents 3.4%, BB 1.9%, 
ACEI/ARB 6.8%, statins 1.4%)[46].  
Usage of secondary prevention medication after ACS has been assessed in 
studies from countries other than South Africa. A long-term follow up study of 31 
750 patients from discharged from a single centre in the USA after having 
undergone a cardiac procedure for ACS showed usage rates of 56% for aspirin, 
32.8% for BB, 18.3% for ACEI/ARB and 31.5% for lipid lowering medication (LL) 
over a 7 year period[47]. A study of from France using a pharmacy database to 
assess medication adherence of 11604 patients at 30 months after acute 
coronary syndrome found adherence rates of 81.7% for aspirin, 68% for BB, 
77.3% for ACEI/ARB and 76% for statins[48].  
We found 5 studies looking specifically at the adherence rates to secondary 
prevention medication after ACS in the 3 to 12 month period after discharge 
from hospital[49-53]. Eagle et al researchers completed a telephonic 
questionnaire at 6 months of 13 830 patients from the Global Registry of Acute 
Coronary Events (GRACE) database. They found adherence rates of 92.7% for 
aspirin, 87.7% for BB, 80.2% for ACEI/ARB and 87.3% for lipid lowering agents 
(LL) [49]. Yufang et al performed a telephonic interview at 6 months after ACS in 
2521 patients recruited into the Clinical Pathways for Acute Coronary 
Syndromes in China (CPACS) study. They found adherence rates of 95.1% for 
aspirin, more than 100% for BB (due to BB being added in the period between 
discharge and interview), 89.4% for ACEI/ARB and 81.8% for LL[50].  Melloni et 
al followed up 1077 patients from the Medication Applied and Sustained Over 
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Time (MAINTAIN) database with a telephonic questionnaire at 3 months. They 
found adherence rates of 93.4% for aspirin, 89.9% for BB, 83.1% for ACEI/ARB 
and 88.8% for LL[51]. A small trial from a single centre in the USA performed 
telephonic interviews of 208 patients 6 to 12 months after ACS and found 
adherence rates of 92.2% for aspirin, 88.6% for BB, 93% for ACEI/ARB and 
91.7% for LL[52]. Results of these 4 studies[49-52] can be found in Table 2. Rates 
of prescribing of secondary prevention medication at discharge in these studies 
vary significantly and must be interpreted in the context of the time during which 
the patients were treated for ACS. There has been significant advancement in 
evidence for secondary prevention therapy after ACS in the last 2 decades, and 
this is reflected in the gradual increase in prescribing rates of these medications 
in more recent years. 
A recent study from Malaysia had 190 patients at routine 6 month follow up 
appointments after ACS complete a standardized questionnaire assessing 
adherence with the Morisky Medication Adherence Scale (MMAS). They found 
only 18.4% of patients reporting a high level of adherence to secondary 
prevention medication, while 51.1% reported medium adherence, and 30.5% 
low adherence[53]. 
We found another 2 studies looking at usage of medication in the 3 to 6 month 
period after ACS, but not giving prescribing rates at discharge, therefore not 
allowing us to assess adherence rates[54,55]. A multi-centre study from the USA 
assessed 1135 patients using a pharmacy database 3 months after ACS, and 
found the percentage of patients filling out at least one prescription for 
medication to be 63.9% for BB, 51.8% for ACEI/ARB and 62.6% for statins. 
There was no record of aspirin use[54]. A very big study from Finland looked at 
the filling of prescriptions after ACS for 53 353 patients using a countrywide 
pharmacy database found that in the time period of 1 to 90 days after discharge, 
85% of patients filled prescriptions for BB, and 72% for LL. This dropped to 75% 
for BB and 66% for LL at 91-180 days[55]. 
It is thus evident from the literature that prescribing rates at discharge of 
secondary prevention medication vary depending on the area or centre in which 
the study took place and the time frame in which data was collected. Adherence 
rates for each medication varies between 80.2% and 100% in the studied 
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populations. Data from South Africa looking at adherence rates after ACS is 
lacking.  
 
Smoking Cessation Rates after Acute Coronary Syndrome in South Africa: 
There are no published studies looking specifically at smoking cessation rates 
after ACS in South Africa. Evidence from the PURE study shows a clear link 
between smoking cessation after coronary heart disease or stroke event, and 
country income category, with cessation rates highest in upper income 
countries, and decreasing along with income category of the country. The 
smoking cessation rate in upper-middle-income countries, into which group 
South Africa is included, was found to be 54.6%[56]. Published smoking 
cessation rates after ACS vary between 33% and 69.9%[26,57-60]. In each of 
these studies there is significant variability in cessation rates according to age, 
gender, income category and other factors. It is clear from 2 of the studies that 
the majority of smoking relapses occur within the first month after the event[26,59].  
 
Need for Further Research: 
There were no published studies looking specifically at the use of secondary 
prevention medication and smoking cessation rates after acute coronary 
syndrome in South Africa. We have identified this as an important gap in our 
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Tables and Figures: 
Table 1: Methods of Measuring Adherence* 
Test Advantages Disadvantages 
Direct Methods   
Directly observed therapy Most accurate Patients can hide pills in the 
mouth and then discard them; 
impractical for routine use 
Measurement of the level of 
medicine or metabolite in blood 
Objective Variations in metabolism and 
“white-coat adherence” can 
give a false impression of 
adherence; expensive 
Measurement of the biologic 
marker in blood 
Objective; in clinical trials, can 
also be used to measure 
placebo 
Requires expensive 
quantitative assays and 
collection of bodily fluids 
Indirect Methods   
Patient questionnaires, patient 
self-reports 
Simple; inexpensive; the most 
useful method in the clinical 
setting 
Susceptible to error with 
increases in time between 
visits; results are easily 
distorted by the patient 
Pill counts Objective, quantifiable, and 
easy to perform 
Data easily altered by the 
patient (e.g. pill dumping) 
Rates of prescription refills Objective; easy to obtain data A prescription refill is not 
equivalent to ingestion of 
medication; requires a closed 
pharmacy system 
Assessment of the patient’s 
clinical response 
Simple; generally easy to 
perform 
Factors other than medication 
adherence can affect clinical 
response 
Electronic medication monitors Precise; results are easily 
quantified; tracks patterns of 
taking medication 
Expensive; required return 
visits and downloading data 
from medication vials 
Measurement of physiologic 
markers (e.g heart rate in 
patients taking beta-blockers) 
Often easy to perfrom Marker may be absent for other 
reasons (e.g. increased 
metabolism, poor absorption, 
lack of response) 
Patient diaries Help to correct for poor recall Easily altered by patient 
When the patient is a child, 
questionnaire for caregiver or 
teacher 
Simple; objective Susceptible to distortion 
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Table 2: Comparison of Discharge Prescribing and Adherence rates 
Between 4 Studies 
Study Eagle et al * Yufang et al † Melloni et al ‡ Sud et al § 
 DC FU AR DC FU AR DC FU AR DC FU AR 
Aspirin 90.1 82.9 92 92.7 88.2 95.1 93.4 87.2 93.4 94.7 87.3 92.2 
BB 56 49.1 87.7 70 71.8 100 91.2 82 89.9 90.3 80 88.6 
ACEI/ARB 17.2 13.8 80.2 75.6 67.6 89.4 69.2 57.5 83.1 71 66 93 
LL 45.7 39.9 87.3 80.4 65.8 81.8 89.9 79.8 88.8 83.3 76.4 91.7 
 
All numbers are percentages, DC = Medication use at discharge, FU = Medication use at follow up, AR = Adherence 
rate  
* Eagle et al. Adherence to Evidence-Based Therapies after Discharge for Acute Coronary Syndrome: An Ongoing 
Prospective, Observational Study. Am J Med. 2004;117:73-81 
† Yufang Bi et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time 
of hospital discharge and 1 year after hospitalization: Results from the Clinical Pathways for Acute Coronary Syndromes 
in China (CPACS) study. Am Heart J 2009;157(3):509-516 
‡ Melloni C et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J 
Cardiol. 2009 Jul 15;104(2):175-81 
§ Sud A, Kline-Rogers EM, Eagle KA, Fang J, Armstrong DF, Rangarajan K, Otten RF, Stafkey-Mailey DR, Taylor SD, 
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PART C: MANUSCRIPT 
 
Achievement of Secondary Prevention Goals 6 to 9 months after Acute 
Coronary Syndrome – a Retrospective, Cross-Sectional Analysis  
 
Bradley Griffiths, MBChB, Maia Lesosky, PhD, Mpiko Ntsekhe, MD PhD 
 
Abstract 
Background. Good evidence exists to support the use of secondary prevention 
medications (aspirin, statins, beta-blockers and angiotensin-converting enzyme 
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)) and smoking 
cessation in patients after acute coronary syndromes (ACSs). Little is currently 
known about adherence to medication and smoking behaviour after discharge 
in South Africa. 
Methods. We conducted a cross-sectional analysis of all patients with a 
diagnosis of ACS discharged from the Coronary Care Unit at Groote Schuur 
Hospital, Cape Town, between 15 November 2011 and 15 April 2012. Patients 
were telephoned 6 - 9 months after discharge and completed a standardised 
questionnaire detailing current medication use, reasons for non-adherence, and 
smoking status. 
Results. Prescribing of secondary prevention medications at discharge was 
high (aspirin 94.5%, statins 95.7%, beta-blockers 85.4%, ACEIs/ARBs 85.9%), 
and 70.7% of patients were discharged on a combination of all four drugs. At 6 - 
9-month follow-up, the proportion using these medications had dropped by 
8.9% for aspirin, 10.1% for statins, 6.2% for beta-blockers and 17.9% for 
ACEIs/ARBs. Only 47.2% remained on all four drugs, a reduction of 23.5%. Of 
the 56.0% of patients who were smokers, 31.4% had stopped smoking.  
Conclusions. A significant decline in adherence to recommended therapy 6 - 9 
months after discharge and a poor rate of smoking cessation suggest that 
efforts to educate patients about the importance of long-term adherence need 
to be improved. Furthermore, more effective interventions than in-hospital 
reminders about the hazards of smoking are needed to improve smoking 
cessation. 




The incidence of ischaemic heart disease (IHD) is on the rise in Africa. Recent 
projections suggest that by 2030 non-communicable diseases (NCDs) will 
become a leading cause of death on the continent, surpassing HIV/AIDS.[1] In 
the South African National Burden of Disease Study in 2000,[2] IHD was found 
to be the largest single cause of death in the Western Cape Province (12%), 
followed by stroke (8.8%) and HIV/AIDS (8.4%), and non-communicable 
diseases accounted for a larger proportion of deaths in the Western Cape 
(58%) than in the rest of South Africa (SA) (38%). In a subsequent study,[3] 
mortality from IHD in Cape Town was found to be very similar to HIV/AIDS (76 v. 
83 deaths per 100 000 population, respectively), and IHD featured as the 
leading cause of death from non-communicable diseases. The Second National 
Burden of Disease Study is nearing completion and will give us more current 
data on mortality trends. The epidemiological transition of cardiovascular 
disease described by Yusuf et al.[4] suggests that with progression from under-
development to industrialisation we can expect an increasing burden of 
degenerative disease, particularly IHD and stroke. 
The use of evidence-based optimal medical therapy (dual antiplatelet therapy, 
statins, beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or 
angiotensin receptor blockers (ARBs)) after acute coronary syndrome (ACS) is 
known to reduce 6-month mortality by up to 87%.[5] Patients who continue to 
smoke after an ACS have a significantly increased risk of a future acute 
myocardial infarction (MI) compared with those who quit.[6]  Furthermore, 
smoking in the presence of established IHD is associated with a significantly 
increased risk of death, including sudden cardiac death. Over an 8-year period, 
smoking cessation reduces this risk to levels comparable to that for people who 
have never smoked.[7] Despite this, medication adherence and smoking 
cessation in patients after discharge is often disappointing.[6-9] Results from the 
Prospective Urban Rural Epidemiology (PURE) study suggest that in SA, and in 
countries with similar income profiles, use of these medicines in patients with 
coronary heart disease at a median follow-up period of 4 years varies between 
21.1% and 31%, compared with 46.5% and 70.9% for upper-income countries. 
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These figures are even lower when Africa as a whole is compared with other 
areas.[10] The reasons for medication discontinuation are diverse, and include 
high cost of obtaining medicine, high pill burden and lower level of education.[11] 
To date there are no published SA data on the medium- to long-term (>6 
months) use of secondary prevention medication and smoking cessation among 
patients discharged from hospital after an ACS. We designed this cross-
sectional study to assess the continued use of four selected drug classes and 
rates of smoking cessation at a follow-up period of 6 - 9 months post discharge 




Cross-sectional analysis with retrospective subject identification. 
 
Study population 
Groote Schuur Hospital is an 893-bed state-funded tertiary hospital in Cape 
Town, SA. It has a 6-bed coronary care unit (CCU) and a cardiac 
catheterisation laboratory. Patients who are admitted to the CCU either present 
directly to the emergency unit or are referred from secondary-level institutions. 
Those who survive their acute cardiac insult are discharged home on optimal 
medical therapy and advised about smoking cessation. Clopidogrel, the only 
P2Y12 receptor antagonist available in our setting and now widely available, was 
only offered to those patients who underwent percutaneous coronary 
intervention during the study period, owing to funder-induced prescribing 
limitations at the time. Apart from a limited discussion about the hazards of 
smoking and its adverse effects on coronary artery disease, no specific smoking 
cessation guidance is offered. Long-term care and follow-up take place at the 
community health centre closest to the patient’s home. Medication is supplied 
free of charge to patients who are pensioners, unemployed, or earn less than 
R36 000 per annum, which includes the vast majority of patients admitted to the 
unit.  
We retrospectively enrolled all patients discharged alive from the CCU with a 
final diagnosis of unstable angina pectoris, non-ST elevation MI or ST-elevation 
MI during the 5-month period between 15 November 2011 and 15 April 2012. In 
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each case the consultant cardiologist in charge of the patient’s care made the 
diagnosis.  
Approval to conduct the study was obtained from the Human Research Ethics 
Committee, Faculty of Health Sciences, University of Cape Town. 
 
Data collection 
A medical record review was performed and a standardised data capture form 
completed for each eligible patient. Information gathered included demographic 
characteristics, income group, comorbid conditions, medication use on 
admission, smoking status, ACS diagnosis, ACS in-hospital treatment, length of 
stay and discharge medication.  
The principal author performed follow-up via a telephone call with the patient or 
primary caregiver at a time period between 6 and 9 months after discharge. A 
Xhosa-speaking interpreter performed three of the interviews under the 
guidance of the principal author, and a single patient was contacted by email. 
Verbal informed consent for enrolment into the study was obtained at this time 
from the patient or caregiver, and it was made clear that the telephone call was 
for study purposes only.  
Patients were encouraged to fetch their current medications and actively list 
them over the telephone. Where a medication of interest was not listed, the 
patient was asked why this was the case. They were then asked a standardised 
smoking question: ‘Do you smoke every day, only some days, or never?’ Any 
reported smoking classified the patient as an ongoing smoker.  
Interviews were conducted primarily in English, Afrikaans or Xhosa only being 
used if the patient was unable to communicate in English or requested 
otherwise, and the interviewer did not identify himself as a doctor unless 
specifically asked.  Where behaviour hazardous to health was identified during 
the interview, such as ongoing smoking or non-adherence to medication, this 
was addressed prior to completing the interview. 
 
Statistical analysis 
Means and standard deviations were calculated for the full data and various 
data subsets. Comparisons of differences between groups were calculated 
using Fisher’s exact test or the Wilcoxon sum rank test (for categorical and 
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continuous variables), as appropriate. A significance level of p<0.05 was used. 




A total of 164 patients with a diagnosis of ACS were discharged alive from the 
CCU and were therefore eligible for enrolment into the study. Their mean age 
was 58.6 years, and 97 (59.1%) were male. The baseline demographic 
variables, type of ACS and inpatient treatment strategy are summarised in 
Table 1.  
Of the 164 patients enrolled in the study, 125 (76.2%) completed follow-up 
interviews. Two patients (1.6%) fell outside the planned follow-up range of 6 - 9 
months (9.5 and 10.75 months), but were included for the sake of completeness 
and the low likelihood of two individuals making a difference to the results. Of 
the remaining patients, 19 (11.6%) had died, 19 (11.6%) were not contactable, 
and 1 (0.6%) declined participation (Fig. 1). The patients who died or were lost 
to follow-up were more likely to have received medical treatment only (p=0.01), 
were less likely to have undergone coronary angiography (p=0.01), and were 
significantly older (p<0.01). 
The overall rate of revascularization was 42% which is low when compared to 
similar studies. This is in part due to resource limitation and is in keeping with 
current hospital ACS management protocols.  
 
Medication use at discharge and at 6 - 9 months’ follow-up 
Of the 164 patients enrolled in the study, 155 (94.5%) were discharged on 
aspirin. Of the patients followed up (N=125), 85.6% (n=107) remained on this 
medication, a reduction of 8.9% (p=0.01). Factors associated with ongoing 
aspirin use, by univariate analysis, were a prior diagnosis of IHD (p=0.01) and 
undergoing coronary angiography (p<0.01). Reasons given for aspirin non-
adherence were dyspepsia (n=3), iron deficiency anaemia (n=1), introduction of 
warfarin therapy (n=1), and not realising the importance of continued use (n=7). 
Statins were prescribed to 157 patients (95.7%) at discharge. At follow-up 
85.6% (107/125) remained on this medication, a reduction of 10.1% (p<0.01). 
The only factor associated with continued use was a diagnosis of 
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hypercholesterolaemia (p=0.02). Reasons given for discontinuation of statins 
were nausea (n=2), and not realising the importance of continued use (n=7). 
Beta-blockers were prescribed for 140 patients (85.4%) at discharge. At follow-
up, 79.2% (99/125) remained on this medication, a reduction of 6.2% (p<0.01). 
Factors associated with adherence were hypercholesterolaemia (p<0.01), a 
prior diagnosis of IHD (p<0.01), and female gender (p=0.02). Reasons given for 
discontinuation were doctor-initiated cessation due to a reduced heart rate 
(n=2), and not realising the importance of continued use (n=11). 
ACEIs/ARBs were prescribed for 141 patients (85.9%) at discharge. At follow-
up, 68.0% (85/125) were still using this medication, the largest reduction in use 
for any of the four drug classes at 17.9% (p<0.01). Ongoing use was associated 
with a prior diagnosis of IHD (p=0.04). Reasons given for discontinuation were 
angio-oedema (n=1), cough (n=4), doctor-initiated cessation due to low blood 
pressure (n=4), and not realising the importance of continued use (n=12). 
The number of patients discharged on a combination of all four drug classes 
was 116 (70.7%). Of the 125 patients followed up, only 47.2% (n=59) remained 
on all four drugs, a reduction of 23.5% (p<0.01). A total of 5 patients (4.0%) had 
stopped all medications, as they did not realise the importance of ongoing use. 
Results are summarised in Table 2a. There was no significant difference in 
adherence rates found when recalculated to include only paired patients (Table 
2b). 
 
Smoking on admission and at 6 - 9 months’ follow-up 
Of the 125 patients who were followed up, 70 (56.0%) had been active smokers 
on admission to hospital, and 22 of these had had stopped smoking by the time 
of the interview, representing a smoking cessation rate of 31.4%.  One patient 
had taken up smoking for the first time after discharge. The only factor 
independently associated with an increased rate of smoking cessation, by 
univariate analysis, was a longer length of hospital stay (p<0.01). We could find 
no relationship between smoking cessation rate and age, gender, income 
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Discussion 
There was good early initiation of secondary prevention medication after ACS in 
our cohort of patients. It has been shown that patients who do not start 
medication shortly after the acute event are unlikely to ever have medication 
added, and a focused effort to start treatment in the immediate post-infarction 
period is likely to provide long-term benefit.[12] When we compare these findings 
with those of the Clinical Pathways for Acute Coronary Syndromes in China 
(CPACS)[8] and the Global Registry of Acute Coronary Events (GRACE)[9] 
studies, our prescribing rates for the four selected drugs at discharge after ACS 
are higher for all drug classes (Table 3 and Fig. 2). Since both the above 
studies used the same method of follow-up as we did, namely telephone calls 
and active listing of medications, they provide a reasonable comparison. The 
CPACS investigators felt that there was a significant gap between evidence and 
practice in medication prescribing after ACS, which was not found in our study. 
It should be noted that the low rates of prescribing of secondary prevention 
medication found in the GRACE study may in part be because the data were 
collected from 1999 to 2003, when less emphasis was placed on these 
medications. Our finding of a high early initiation rate of all four recommended 
drugs is important and demonstrates that adherence to best-practice guidelines 
in our setting is feasible. 
We found a significant increase in the rate of non-adherence to the selected 
medications in our group of patients beyond 6 months. Medication cessation for 
appropriate reasons, such as ACEI-induced angio-oedema or beta-blocker-
induced symptomatic bradycardia, is unavoidable and expected for a minority of 
patients. What is more concerning is that patients stopped medication because 
they did not realise the importance of ongoing use, which was found to be a 
reason for non-adherence for each of the four drug classes, and for the 5 
patients who stopped all four drugs completely. Rates of discontinuation of 
medication were higher for most of the drug classes when compared with the 
CPACS and GRACE studies (Table 3 and Fig. 2), the exceptions being lipid-
lowering agents when compared with CPACS (a 10.1% drop-off in adherence v. 
14.6%) and beta-blockers when compared with GRACE (6.2% v. 6.9%). It is not 
clear from our data why the rates of non-adherence are higher. There is not a 
clear link to a language barrier, as all but 3 of the patients could speak English 
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or Afrikaans, both of which are spoken in the CCU by doctors and nursing staff. 
There was also no demonstrable link between income category and adherence, 
and SA and China are both rated as upper middle-income countries by the 
World Bank Country Classification, so adherence rates based purely on income 
would be expected to be similar. It is possible that level of education and insight 
into disease could play a role, but these were not included in our questionnaire. 
No patient mentioned a shortage of medication at a local clinic as a reason for 
discontinuation. The frequent reporting of non-adherence to medication due to 
not understanding the importance of ongoing use implies that good 
communication with the patient during the index hospital admission, with a 
focus on education about the disease and future treatment, is essential. 
Enhanced communication between treating doctor and patient, as well as 
involving ancillary health care providers such as nursing staff and pharmacists, 
have both been shown to improve adherence, both during admission and 
through community-based cardiac rehabilitation programmes.  Innovative 
measures such as the use of short message service (SMS) reminder 
technology for mobile phones, which has been demonstrated to improve 
adherence to antiretroviral medication in SA and to other chronic medications 
elsewhere, should be looked at to improve adherence in our setting. 
More of our patients continued to smoke after an ACS than has been found in 
similar studies. Evidence from the PURE study shows a clear link between 
smoking cessation after a coronary heart disease or stroke event and country 
income category, with cessation rates highest in upper-income countries, and 
decreasing with declining income category of the country.[13] The smoking 
cessation rate in upper middle-income countries such as SA was found to be 
54.6%,[13]  which is still higher than the 31% rate in our group. We did not ask 
patients whether they had tried to stop smoking, or indeed whether they wanted 
to try to stop, so the rate of failed attempts at smoking cessation is unknown. 
The Western Cape is known to have the highest smoking rate of all the SA 
provinces, at 44.7% of men and 27% of women.[14] A recent Cochrane review 
found that intensive behavioural interventions in hospitalised patients, followed 
by at least a month of outpatient supportive contact, was effective at 
significantly improving smoking cessation rates, and it should be considered as 
an option in this group of patients. The addition of nicotine replacement therapy 
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in gum or patch form further improves smoking cessation. At present there is 
not sufficient evidence to prove that bupropion or varenicline in addition to 
intensive counselling in hospitalised patients increases cessation rates over 
intensive counselling alone.[15] The smoking cessation rates in our cohort 
suggest that adoption of these and other evidence-based methods of 




Our study has a number of limitations. We measured adherence by self-report, 
with no electronic or pill count data to back up our findings. Although this 
method of active listing of medications over the telephone tends to overestimate 
adherence, it has been used successfully in similar studies[8,9,11] and is highly 
specific. While measurement of smoking by self-report can lead to an 
overestimation of smoking cessation, this method has been shown to correlate 
well with cotinine testing in most studies. Other limitations include enrolling 
patients from only a single urban tertiary centre, having a relatively small 
sample size, and borderline significance of univariate analyses. Not knowing 
the medication adherence and smoking cessation rates of those patients who 
died is another limitation, as this information may have improved insight into 
mortality in this group of patients. These factors raise the concern that our 
findings may not be representative of the population as a whole, or indeed to 
secondary level hospitals in our area. In order to avoid selection bias at 
enrolment, we included every patient with ACS discharged alive from the CCU 
over the selected 5-month period, and did not limit inclusion to those patients 
who were followed up at our institution. SA is a diverse country with broad 
variations in culture, income and access to healthcare, and a similar multicentre, 
prospective study in future could enable us to better understand the challenges 
with regard to medication adherence and smoking cessation after ACS.  
 
Conclusion 
This study has provided valuable insight into prescribing practices, medium-
term adherence patterns after ACS, and smoking cessation rates beyond 6 
months, areas for which there are currently no published data in our setting. 
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Three findings were of particular importance: (i) we found that our prescribing of 
secondary prevention medication at discharge is high (70.7% for the four-drug 
combination); (ii) we noted that a reasonably large proportion of our patients are 
discontinuing medication within a 6 - 9-month period (23.5% for the four-drug 
combination); and (iii) we demonstrated that a large proportion (68.6%) of 
patients who were active smokers on admission to hospital continued to smoke, 
giving a cessation rate of 31.4%. Given the importance of smoking cessation in 
improving short- and long-term outcomes, more focused strategies to improve 





1. Ntsekhe M, Damasceno A. Recent advances in the epidemiology, outcome, 
and prevention of myocardial infarction and stroke in sub-Saharan Africa. Heart 
2013 Sep; 99(17): 1230-5 [http://dx.doi.org/10.1136/heartjnl-2012-303585] 
[PMID: 23680888] 
 
2. Bradshaw D, Nannan N, Laubscher R et al. South African National Burden of 
Disease Study 2000. Estimates of Provincial Mortality: Western Cape Province. 
Cape Town: South African Medical Research Council, 2003. 
http://www.mrc.ac.za/bod/westerncape.pdf (accessed 26 November 2013) 
 
3. Groenewald P, Bradshaw D, Daniels J et al. Cause of Death and Premature 
Mortality in Cape Town, 2001-2004. Cape Town: South African Medical 
Research Council, 2007. http://www.mrc.ac.za/bod/capetownreport.pdf 
(accessed 26 November 2013) 
 
4. Yusuf S, Reddy S, Ounpuu S, Anand S. Global Burden of Cardiovascular 
Diseases. Part I: General Considerations, the Epidemiologic Transition, Risk 
Factors, and Impact of Urbanisation. Circulation. 2001;104(22):2746-53. 
[http://dx.doi.org/10.1161/hc4601.099487] [PMID: 11723030] 
 
5. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. 
11	   	   	  
Impact of combination evidence-based medical therapy on mortality in patients 
with acute coronary syndromes. Circulation 2004;109(6):745–749 
[http://dx.doi.org/10.1161/01.CIR.0000112577.69066.CB ] [PMID: 14970110] 
 
6. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association 
of diet, exercise, and smoking modification with risk of early cardiovascular 
events after acute coronary syndromes. Circulation. 2010;121(6):750-8. 
[http://dx.doi.org/10.1161/circulationaha.109.891523] [PMID: 20124123] 
 
7. Goldenberg I, Jonas M, Tenenbaum A et al. Current smoking, smoking 
cessation, and the risk of sudden cardiac death in patients with coronary artery 
disease. Arch Intern Med. 2003 Oct 27;163(19):2301-5. 
[http://dx.doi.org/10.1001/archinte.163.19.2301][PMID: 14581249].  
 
8. Bi Y, Gao R, Patel A et al. Evidence-based medication use among Chinese 
patients with acute coronary syndromes at the time of hospital discharge and 1 
year after hospitalization: Results from the Clinical Pathways for Acute 
Coronary Syndromes in China (CPACS) study. Am Heart J 2009;157(3):509-
516 [http://dx.doi.org/10.1016/j.ahj.2008.09.026] [PMID: 19249422] 
 
9. Eagle KA, Kline-Rogers E, Goodman SG et al. Adherence to Evidence-
Based Therapies after Discharge for Acute Coronary Syndromes: An Ongoing 
Prospective, Observational Study. Am J Med. 2004;117(2):73– 81. 
[http://dx.doi.org/10.1016/j.amjmed.2003.12.041] [PMID: 15234641] 
 
10. Yusuf S, Islam S, Chow CK et al. Use of secondary prevention drugs for 
cardiovascular disease in the community in high-income, middle-income, and 
low-income countries (the PURE study): a prospective epidemiological survey. 
Lancet 2011;378(9798):1231-43 [http://dx.doi.org/10.1016/S0140-
6736(11)61215-4] [PMID: 21872920] 
 
11. Melloni C, Alexander KP, Ou FS et al. Predictors of early discontinuation of 
evidence-based medicine after acute coronary syndrome. Am J Cardiol. 2009 
Jul 15;104(2):175-81 [http://dx.doi.org/10.1016/j.amjcard.2009.03.013] [PMID: 
12	   	   	  
19576342] 
 
12. Gislason GH, Rasmussen JN, Abildstom SZ et al. Long-term compliance 
with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after 
acute myocardial infarction. Eur Heart J. 2006 May;27(10):1153-8 
[http://dx.doi.org/10.1093/eurheartj/ehi705] [PMID: 16399775] 
 
13. Teo K, Lear S, Islam S et al. Prevalence of Healthy Lifestyle Among 
Individuals With Cardiovascular Disease in High-, Middle- and Low- Income 
Countries. The Prospective Urban Rural Epidemiology (PURE) Study. JAMA. 
2013;309(15):1613-1621 [http://dx.doi.org/10.1001/jama.2013.3519] [PMID: 
23592106] 
 
14. Chopra M, Steyn N, Lambert V. Western Cape Burden of Disease 
Reduction Project: Decreasing the Burden of Cardiovascular Disease. Final 
Report 2007 
http://www.westerncape.gov.za/text/2007/6/cd_volume_6_cardiovascular_disea
ses.pdf (Accessed 26 November 2013) 
 
15. Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking 
cessation in hospitalised patients. Cochrane Database Syst Rev. 2012 May 






13	   	   	  
Tables and Figures 
 
Table 1. Demographic characteristics of patients enrolled, completing 














Age (years), mean (±SD) 58.6 (11.2) 57.0 (10.9) 63.8 (11.0) <0.01 
Male, n (%) 97 (59.1) 71 (56.8) 26 (66.7) 0.35 
Income Category, n (%)    0.08 
          Unemployed/Pensioner  47 (28.6) 31 (24.8) 16 (41.0)  
          Income < R36000 per annum 85 (51.8) 66 (52.8) 19 (48.7)  
          Income R36000 to R72000 per annum 14 (8.5) 14 (11.2) -  
          Income >R72000 per annum 13 (7.9) 9 (7.2) 4 (10.3)  
          Private Medical Aid/Foreigner 4 (2.4) 4 (3.2) -  
          Unknown 1 (0.6) 1 (0.8) -  
Medical History, n (%)     
          Hypertension 99 (60.3) 71 (56.8) 28 (71.8) 0.09 
          Diabetes Mellitus 51 (31.0) 36 (28.8) 15 (38.5) 0.23 
          Hypercholesterolaemia 73 (44.5) 57 (45.6) 16 (41.0) 0.85 
          IHD 83 (50.6) 61 (48.8) 22 (56.4) 0.36 
Current smoker, n (%) 90 (54.8) 70 (56.0) 20 (51.3) 0.09 
Diagnosis, n (%)    0.48 
          ST-elevation MI 59 (35.9) 44 (35.2) 15 (38.5)  
          Non ST-elevation MI 77 (46.9) 57 (45.6) 20 (51.3)  
          Unstable angina pectoris 28 (17.0) 24 (19.2) 4 (10.3)  
Treatment, n (%)    0.01 
          Medical only 95 (57.9) 65 (52.0) 30 (76.9)  
          PCI 59 (35.9) 50 (40.0) 9 (23.1)  
          Coronary artery bypass graft  10 (6.09) 10 (8.0) -  
Angiogram (including PCI), n (%) 112 (68.2) 92 (73.6) 20 (51.3) 0.01 
Length of Stay (days) - mean (±SD) 3.018 (1.9) 2.98 (2.0) 3.13 (1.7) 0.43 
SD = standard deviation; IHD = ischaemic heart disease (previous myocardial infarction or unstable angina pectoris);  
MI = myocardial infarction; PCI = percutaneous coronary intervention. 
 
	   	  
14	   	   	  









Discharged	  alive	  with	  a	  




Not	  contactable	  (N=19)	   Declined	  participation	  (N=1)	  
Died	  (N=19)	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Table 2a. Medication use at discharge and follow up.  
 
 Discharge, N=164, 
n (%) 
Follow up, N=125, 
n (%) 
Reduction in Use 
(%) 
P-value 
Aspirin 155 (94.5) 107 (85.6) 8.9 <0.01 
Statin 157 (95.7) 107 (85.6) 10.1 <0.01 
Beta-blocker 140 (85.4) 99 (79.2) 6.2 <0.01 
ACEI/ARB 141 (85.9) 85 (68.0) 17.9 <0.01 
4-drug combination 116 (70.7) 59 (47.2) 23.5 <0.01 
ACEI/ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker 
 
Table 2b. Medication use at discharge and follow up for paired patients 
 
 Discharge, N=125, 
n (%) 
Follow up, N=125, 
n (%) 
Reduction in Use 
(%) 
P-value 
Aspirin 118 (94.4) 107 (85.6) 8.8 <0.01 
Statin 118 (94.4) 107 (85.6) 8.8 <0.01 
Beta-blocker 109 (87.2) 99 (79.2) 8 <0.01 
ACEI/ARB 107 (85.6) 85 (68.0) 17.6 <0.01 
4-drug combination 92 (73.6) 59 (47.2) 26.4 <0.01 
ACEI/ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker 
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Table 3. Comparison between medication use at discharge and follow up 
in the present study and two similar studies.  

























157 (95.7) 107 (85.6) -10.1 2332 (80.4) 1654 (65.8) -14.6 6320  (45.7) 5522 (39.9) -6.1 
Beta 
Blocker 
140 (85.4) 99 (79.2) -6.2 2031 (70.0) 1798 (71.8) +1.8 7738  (56.0) 6796 (49.1)  -6.9 
ACEI/ARB 141 (85.9) 85 (68.0) -17.9 2194 (75.6) 1694 (67.2) -8.4 2379  (17.2) 1906 (13.8) -3.4 
4 Drug 
Combo 
116 (70.7) 59 (47.2) -23.5 1384 (47.7) 1088 (43.6) -4.1 NA NA NA 
DC = medication prescribed at discharge; FU = medication use reported at follow-up; Diff. = difference between DC and 
FU; ACEI/ARB – angiotensin converting enzyme inhibitor or angiotensin receptor blocker; CPACS = Clinical Pathways 
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Figure 2: Graphic representation of the comparison between medication 
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Appendix 1: Interview Structure 
1. Introduction:  
“Bradley Griffiths from Groote Schuur Hospital Cardiac Clinic” – will not 
introduce myself as a doctor as this may influence honesty of responses to 
questions. Not an ethical problem as makes no difference to subject if 
interviewer is a doctor or not. 
2. Explanation of study:  
“Phoning to collect information from patients who have previously been 
admitted to the ICU with a heart attack in order to improve the service to 
future patients. Participation is voluntary and anonymous, and will not 
influence any further treatment at Groote Schuur or elsewhere. This is a 
study and is not aimed at providing a health service at the present time”  
3. Opportunity for subject to ask questions, raise concerns or decline 
participation 
 
4. Study question 1:  
“With regard to smoking, do you smoke cigarettes every day, some days or 
never?”- any answer other than “never” will classify subject as a smoker. 
5. Study question 2:  
“Please could you list the medication you are taking at present” – subject will 
be encouraged to fetch actual medication and read out list  
If medication listed above is different to discharge medication, a follow up 
question will be asked. This will need to be individualized according to the 
medication listed. Dose adjustments will be documented but ignored as far 
as interview structure is concerned. For example:  
“What do you think is the main reason for you not taking your prescribed 
medication?”  
or 
 “Do you know why you no longer take Atenolol?” 
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6. Opportunity for interviewer to give advice if behavior hazardous to 
health is picked up – if subject is a smoker, will be advised that this is 
hazardous to health; if subject is not adherent to medication, will be advised 
that this is hazardous to health. Specific advice with regard to how to renew 
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Appendix 2: Data Capture Sheet 
 
NAME & HOSP NO.     
DOB & SEX     
RESIDENTIAL AREA    
PHONE NUMBERS     
     
DOA & DOD     
DIAGNOSIS (ACS)    
TREATMENT    
COMORBIDITIES     
     
     
ADMISSION MEDS     
     
     
     
ADMISSION SMOKING    
DISCHARGE MEDS     
     
     
      
   
CURRENT MEDS     
     
     
     
REASON(S) FOR NON-   
COMPLIANCE 
CURRENT SMOKING     
ENGLISH    
RIP     
NOT CONTACTABLE     
REFUSED     
DATA CAPTURER    
DATE AND TIME    
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Appendix 3: Human Research Ethics Committee Approval Letter 
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